DexCom, Inc. (DXCM) PEG Ratio: 0.66
Is DexCom, Inc.’s PEG ratio high or low?
DexCom, Inc.'s PEG ratio of 0.66 is 92% below its 5-year average of 8.76, near the low end of its 5-year range (0.19–39.32).
96.70% below its 12-month average of 19.99.
DXCM PEG Ratio Chart
DXCM Average PEG Ratio Chart
DXCM Current vs Average PEG Ratio Chart
DXCM PEG Ratio Metrics
PEG RATIO
0.66
PEG RATIO AVG TTM
19.99
PEG RATIO AVG 3Y
10.91
PEG RATIO AVG 5Y
8.76
PEG RATIO AVG 10Y
7.96
PEG RATIO AVG 15Y
5.79
PEG RATIO AVG 20Y
4.57
CURRENT VS TTM AVG
-96.70%
CURRENT VS 3Y AVG
-93.95%
CURRENT VS 5Y AVG
-92.47%
CURRENT VS 10Y AVG
-91.71%
CURRENT VS 15Y AVG
-88.60%
CURRENT VS 20Y AVG
-85.55%
DXCM Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | $28.92B | 0.66 | 19.99 | 10.91 | 8.76 |
| Biogen Inc. (BIIB) | $28.94B | N/A | 0.34 | 0.24 | 0.23 |
| IQVIA Holdings Inc. (IQV) | $30.08B | 6.34 | 8.50 | 5.12 | 3.87 |
| Medline Inc. (MDLN) | $31.40B | N/A | 0.07 | 0.07 | 0.07 |
| Veeva Systems Inc. (VEEV) | $26.31B | 1.42 | 1.47 | 5.64 | 5.88 |
| Centene Corporation (CNC) | $32.26B | N/A | 0.18 | 0.16 | 0.16 |
| Zoetis Inc. (ZTS) | $34.27B | 2.04 | 2.96 | 3.83 | 3.78 |
| Waters Corporation (WAT) | $23.21B | 75.62 | 75.62 | 40.78 | 27.51 |
| United Therapeutics Corporation (UTHR) | $23.15B | 1.16 | 0.84 | 0.59 | 0.59 |
| Mettler-Toledo International Inc. (MTD) | $22.82B | 8.96 | 5.67 | 4.53 | 3.90 |
Growth-Adjusted Valuation
PEG Ratio
0.66
P/E Ratio
32.0
DexCom, Inc. PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. PEG Ratio FAQ
- What is the PEG ratio for DexCom, Inc. (DXCM)?
- The PEG ratio for DXCM stock is 0.66.
- Is DexCom, Inc.'s PEG ratio high or low?
- DexCom, Inc.'s PEG ratio of 0.66 is 92% below its 5-year average of 8.76, near the low end of its 5-year range (0.19–39.32).
- What is the TTM average PEG ratio for DexCom, Inc. (DXCM)?
- The TTM average PEG ratio for DXCM stock is 19.99.
- What is the 3Y average PEG ratio for DexCom, Inc. (DXCM)?
- The 3Y average PEG ratio for DXCM stock is 10.91.
- What is the 5Y average PEG ratio for DexCom, Inc. (DXCM)?
- The 5Y average PEG ratio for DXCM stock is 8.76.
- What is the 10Y average PEG ratio for DexCom, Inc. (DXCM)?
- The 10Y average PEG ratio for DXCM stock is 7.96.
- What is the 15Y average PEG ratio for DexCom, Inc. (DXCM)?
- The 15Y average PEG ratio for DXCM stock is 5.79.
- What is the 20Y average PEG ratio for DexCom, Inc. (DXCM)?
- The 20Y average PEG ratio for DXCM stock is 4.57.
DexCom, Inc. PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2025-12-31 | 0.66 |
| 2024-12-31 | 39.32 |
| 2023-12-31 | 1.39 |
| 2022-12-31 | 2.26 |
| 2020-12-31 | 0.19 |
| 2017-12-31 | 3.95 |
| 2014-12-31 | 7.25 |
| 2013-12-31 | 1.69 |
| 2011-12-31 | 0.47 |
| 2010-12-31 | 0.70 |
| 2009-12-31 | 0.19 |
| 2007-12-31 | 1.17 |
| 2005-12-31 | 0.13 |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach